Research programme: respiratory virus inhibitor - Vybion

Drug Profile

Research programme: respiratory virus inhibitor - Vybion

Alternative Names: Respiratory virus inhibitor research programme - Viral Therapeutics; Virusorb

Latest Information Update: 23 Jun 2008

Price : $50

At a glance

  • Originator Vybion
  • Class Recombinant proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 20 Jun 2008 Merdian Bioscience acquires recombinant proteins portfolio from Vybion
  • 14 May 2008 Vybion executes a letter of intent to sell its recombinant protein business to Meridian Bioscience
  • 24 Aug 2005 This programme is still in active development - (BIO-2005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top